The GLP-1 Analogue Lixisenatide Decreases Atherosclerosis in Insulin-Resistant Mice by Modulating Macrophage Phenotype
Other compounds like mazdutide and survodutide are progressing through development pipelines
Titrate Up to 1 mg or 2.4 mg Weekly Based on Individual Response After patients stabilize on 0.5 mg, the next stage involves titration to higher doses such as 1 mg or, in some cases, up to 2.4 mg weekly
GLP-1 receptor activation slows the entire digestive tract, which can swing between loose and hard stools depending on hydration, diet, and individual physiology
Back Marso, SP, Daniels, GH, Brown-Frandsen, K, et al (28 July 2016) 'Liraglutide and cardiovascular outcomes in type 2 diabetes', New England Journal of Medicine , 375/4, 311-22